TMX-201 is a TLR7 ligand-phospholipid conjugate. TMX-201 shows potent immune stimulatory activity. TMX-201 can be used for breast cancer and melanoma research.
性状
Solid
IC50 & Target[1][2]
TLR7
体外研究(In Vitro)
TMX-201 is more potent cytokine inducer than Imiquimod (HY-B0180) in both mouse and human mononuclear cells. TMX-201 shows less off-target binding compared to Imiquimod. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
The maximum tolerated dose of TMX-201 by i.v. administration is 75 mg/kg.
TMX-201 (4mg/kg, IP) suppresses the growth of established subcutaneous B16 melanoma by 46%, without discernible adverse effects.
TMX-201 (IP or intra-tumor administration), in combination with anti-CTLA4 antibody, significantly suppressed lung metastasis formation in the 4T1 breast cancer model. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, sealed storage, away from moisture and light In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
参考文献
[1]. Dennis A. Carson, et al. Application of novel phospholipid conjugated Toll like receptor 7 ligands for cancer therapy by topical and systemic administration. Cancer Res 2014;74(19 Suppl): 2568.
溶解度数据
In Vitro: DMSO : 50 mg/mL (46.07 mM; ultrasonic and warming and heat to 60°C)配制储备液
[1]. Dennis A. Carson, et al. Application of novel phospholipid conjugated Toll like receptor 7 ligands for cancer therapy by topical and systemic administration. Cancer Res 2014;74(19 Suppl): 2568.